ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-22
DOI
10.1038/s41598-017-10468-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
- (2017) Sara Duhachek-Muggy et al. Molecular Cancer
- Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
- (2016) Tsutomu Takashima et al. LANCET ONCOLOGY
- Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes
- (2015) Yan Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1
- (2015) Lin Wang et al. Oncotarget
- Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes
- (2015) Chiara Focaccetti et al. PLoS One
- The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition
- (2015) Michaël Ruff et al. PLoS One
- Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
- (2014) C. Vulsteke et al. BREAST CANCER RESEARCH AND TREATMENT
- The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression
- (2014) J. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints
- (2014) S V del Rincón et al. ONCOGENE
- Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
- (2013) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins
- (2013) Camilla Fröhlich et al. BIOCHEMICAL JOURNAL
- Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype
- (2013) Hui Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells
- (2013) Qing-ping Wang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials
- (2011) Jordi Ginés et al. Clinical & Translational Oncology
- 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation
- (2011) Guopei Zheng et al. FEBS LETTERS
- Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
- (2011) H. Iwata et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- ADAM12 Transmembrane and Secreted Isoforms Promote Breast Tumor Growth
- (2011) Roopali Roy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The 2011 EBCTCG polychemotherapy overview
- (2011) Carlo Palmieri et al. LANCET
- Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-κB pathway in MCF-7 cells
- (2010) Xuedong Wang et al. FEBS LETTERS
- Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
- (2010) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
- (2009) Sophia B. Lee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- (2009) Pierre Farmer et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More